#NACFC2018 – RPL554 Shows Promising Results in CF Studies
Positive data from preclinical and Phase 2a studies evaluating the investigational cystic fibrosis (CF) treatment RPL554 were presented...
Cystic Fibrosis Lung Function Improved With Triple Therapy
Patients with cystic fibrosis with either 1 or 2 Phe508del alleles who were treated with a drug combination of VX-659, tezacaftor, and...
#NACFC2018 — Vertex Presents Latest Clinical Data on CFTR Modulators
Vertex Pharmaceuticals’ VX-659 or VX-445 in combination with Kalydeco(ivacaftor) and tezacaftor (VX-661) can improve the lung function of...
Scientists Reveal New Cystic Fibrosis Treatments Work Best in Inflamed Airways
New UNC School of Medicine research led by Martina Gentzsch, PhD, and Carla Ribeiro, PhD, suggests that cystic fibrosis drugs used to...
Vertex and Treating CF: High Hopes for Triple Combinations and Gene Therapy Possibilities
Editor’s note: This is third in a four-part series looking at Vertex Pharmaceuticals and its “all in for CF” approach. Here, we look at...
Vertex and Treating CF: 3 Disease-modifying Therapies Make Leap from Lab to Patients
Editor’s Note: This is the second of a four-part series looking at Vertex Pharmaceuticals and its “all in for CF” approach. Here, we...